Liarozole - A novel treatment approach for advanced prostate cancer: Results of a large randomized trial versus cyproterone acetate

Frans J M Debruyne, Robin Murray, Yves Fradet, Jan E. Johansson, Chris Tyrrell, Francesco Boccardo, Louis Denis, J. Michael Marberger, Daniel Brune, Jens Rassweiler, Tony Vangeneugden, Jan Bruynseels, Monique Janssens, Peter De Porre

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Objectives. To compare the efficacy of oral liarozole, the first retinoic acid metabolism-blocking agent (RAMBA) to be developed as differentiation therapy for human solid tumors, with that of cyproterone acetate (CPA), an antiandrogen for the treatment of metastatic prostate cancer. Liarozole promotes differentiation of cancer cells by increasing the intratumoral levels of retinoic acid. Methods. A total of 321 patients with metastatic prostate cancer in relapse after first-line endocrine therapy entered a Phase III international multicenter study (recruitment from February 1992 to August 1994) comparing liarozole (300 mg two times daily) with CPA (100 mg two times daily). Results. Accounting for differences in baseline prognostic factors, the adjusted hazard ratio for survival was 0.74 in favor of liarozole (P = 0.039), indicating a 26% lower risk of death than in patients treated with CPA. Median crude (unadjusted) survival time was the same in the liarozole group as in the CPA group (10.3 months). More patients showed a PSA response (at least 50% reduction in PSA from baseline) when treated with liarozole (20%) than with CPA (4%) (P <0.001). Prostate- specific antigen (PSA) responders had a median survival benefit of 10 months over nonresponders, irrespective of treatment (hazard ratio 0.43; P = 0.0018). PSA response was apparent within 3 months in approximately 90% of patients who responded. Pain improved more in the liarozole group than in the CPA group (P = 0.03). PSA responders had lower median pain scores than nonresponders (1.7 versus 2.5) and better quality of life (median Functional Living Index-Cancer score 108 versus 98) at end point, ie, treatment discontinuation, as well as throughout the treatment period. Among the most frequently occurring adverse events in the liarozole group were dry skin (51% of patients), pruritus (25%), rash (16%), nail disorders (16%), and hair loss (15%). These adverse events were generally mild to moderate in severity and did not affect the overall quality of life score. There were no detectable effects of either treatment on vital signs such as blood pressure, heart rate, electrocardiogram, and body weight. Conclusions. Liarozole is superior to CPA in terms of PSA response, PSA progression, and survival, and is capable of maintaining patients' quality of life. The observed adverse events were mild to moderate in nature. These results show that liarozole is a possible treatment option after first-line endocrine therapy has failed.

Original languageEnglish
Pages (from-to)72-81
Number of pages10
JournalUrology
Volume52
Issue number1
DOIs
Publication statusPublished - Jul 1998

Fingerprint

liarozole
Cyproterone Acetate
Prostatic Neoplasms
Prostate-Specific Antigen
Therapeutics
Survival
Quality of Life
Tretinoin
Pain
Androgen Antagonists
Neoplasms
Vital Signs
Alopecia
Pruritus

ASJC Scopus subject areas

  • Urology

Cite this

Liarozole - A novel treatment approach for advanced prostate cancer : Results of a large randomized trial versus cyproterone acetate. / Debruyne, Frans J M; Murray, Robin; Fradet, Yves; Johansson, Jan E.; Tyrrell, Chris; Boccardo, Francesco; Denis, Louis; Marberger, J. Michael; Brune, Daniel; Rassweiler, Jens; Vangeneugden, Tony; Bruynseels, Jan; Janssens, Monique; De Porre, Peter.

In: Urology, Vol. 52, No. 1, 07.1998, p. 72-81.

Research output: Contribution to journalArticle

Debruyne, FJM, Murray, R, Fradet, Y, Johansson, JE, Tyrrell, C, Boccardo, F, Denis, L, Marberger, JM, Brune, D, Rassweiler, J, Vangeneugden, T, Bruynseels, J, Janssens, M & De Porre, P 1998, 'Liarozole - A novel treatment approach for advanced prostate cancer: Results of a large randomized trial versus cyproterone acetate', Urology, vol. 52, no. 1, pp. 72-81. https://doi.org/10.1016/S0090-4295(98)00129-0
Debruyne, Frans J M ; Murray, Robin ; Fradet, Yves ; Johansson, Jan E. ; Tyrrell, Chris ; Boccardo, Francesco ; Denis, Louis ; Marberger, J. Michael ; Brune, Daniel ; Rassweiler, Jens ; Vangeneugden, Tony ; Bruynseels, Jan ; Janssens, Monique ; De Porre, Peter. / Liarozole - A novel treatment approach for advanced prostate cancer : Results of a large randomized trial versus cyproterone acetate. In: Urology. 1998 ; Vol. 52, No. 1. pp. 72-81.
@article{9b52c940f2b549a19ce9aacb3d2029c9,
title = "Liarozole - A novel treatment approach for advanced prostate cancer: Results of a large randomized trial versus cyproterone acetate",
abstract = "Objectives. To compare the efficacy of oral liarozole, the first retinoic acid metabolism-blocking agent (RAMBA) to be developed as differentiation therapy for human solid tumors, with that of cyproterone acetate (CPA), an antiandrogen for the treatment of metastatic prostate cancer. Liarozole promotes differentiation of cancer cells by increasing the intratumoral levels of retinoic acid. Methods. A total of 321 patients with metastatic prostate cancer in relapse after first-line endocrine therapy entered a Phase III international multicenter study (recruitment from February 1992 to August 1994) comparing liarozole (300 mg two times daily) with CPA (100 mg two times daily). Results. Accounting for differences in baseline prognostic factors, the adjusted hazard ratio for survival was 0.74 in favor of liarozole (P = 0.039), indicating a 26{\%} lower risk of death than in patients treated with CPA. Median crude (unadjusted) survival time was the same in the liarozole group as in the CPA group (10.3 months). More patients showed a PSA response (at least 50{\%} reduction in PSA from baseline) when treated with liarozole (20{\%}) than with CPA (4{\%}) (P <0.001). Prostate- specific antigen (PSA) responders had a median survival benefit of 10 months over nonresponders, irrespective of treatment (hazard ratio 0.43; P = 0.0018). PSA response was apparent within 3 months in approximately 90{\%} of patients who responded. Pain improved more in the liarozole group than in the CPA group (P = 0.03). PSA responders had lower median pain scores than nonresponders (1.7 versus 2.5) and better quality of life (median Functional Living Index-Cancer score 108 versus 98) at end point, ie, treatment discontinuation, as well as throughout the treatment period. Among the most frequently occurring adverse events in the liarozole group were dry skin (51{\%} of patients), pruritus (25{\%}), rash (16{\%}), nail disorders (16{\%}), and hair loss (15{\%}). These adverse events were generally mild to moderate in severity and did not affect the overall quality of life score. There were no detectable effects of either treatment on vital signs such as blood pressure, heart rate, electrocardiogram, and body weight. Conclusions. Liarozole is superior to CPA in terms of PSA response, PSA progression, and survival, and is capable of maintaining patients' quality of life. The observed adverse events were mild to moderate in nature. These results show that liarozole is a possible treatment option after first-line endocrine therapy has failed.",
author = "Debruyne, {Frans J M} and Robin Murray and Yves Fradet and Johansson, {Jan E.} and Chris Tyrrell and Francesco Boccardo and Louis Denis and Marberger, {J. Michael} and Daniel Brune and Jens Rassweiler and Tony Vangeneugden and Jan Bruynseels and Monique Janssens and {De Porre}, Peter",
year = "1998",
month = "7",
doi = "10.1016/S0090-4295(98)00129-0",
language = "English",
volume = "52",
pages = "72--81",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Liarozole - A novel treatment approach for advanced prostate cancer

T2 - Results of a large randomized trial versus cyproterone acetate

AU - Debruyne, Frans J M

AU - Murray, Robin

AU - Fradet, Yves

AU - Johansson, Jan E.

AU - Tyrrell, Chris

AU - Boccardo, Francesco

AU - Denis, Louis

AU - Marberger, J. Michael

AU - Brune, Daniel

AU - Rassweiler, Jens

AU - Vangeneugden, Tony

AU - Bruynseels, Jan

AU - Janssens, Monique

AU - De Porre, Peter

PY - 1998/7

Y1 - 1998/7

N2 - Objectives. To compare the efficacy of oral liarozole, the first retinoic acid metabolism-blocking agent (RAMBA) to be developed as differentiation therapy for human solid tumors, with that of cyproterone acetate (CPA), an antiandrogen for the treatment of metastatic prostate cancer. Liarozole promotes differentiation of cancer cells by increasing the intratumoral levels of retinoic acid. Methods. A total of 321 patients with metastatic prostate cancer in relapse after first-line endocrine therapy entered a Phase III international multicenter study (recruitment from February 1992 to August 1994) comparing liarozole (300 mg two times daily) with CPA (100 mg two times daily). Results. Accounting for differences in baseline prognostic factors, the adjusted hazard ratio for survival was 0.74 in favor of liarozole (P = 0.039), indicating a 26% lower risk of death than in patients treated with CPA. Median crude (unadjusted) survival time was the same in the liarozole group as in the CPA group (10.3 months). More patients showed a PSA response (at least 50% reduction in PSA from baseline) when treated with liarozole (20%) than with CPA (4%) (P <0.001). Prostate- specific antigen (PSA) responders had a median survival benefit of 10 months over nonresponders, irrespective of treatment (hazard ratio 0.43; P = 0.0018). PSA response was apparent within 3 months in approximately 90% of patients who responded. Pain improved more in the liarozole group than in the CPA group (P = 0.03). PSA responders had lower median pain scores than nonresponders (1.7 versus 2.5) and better quality of life (median Functional Living Index-Cancer score 108 versus 98) at end point, ie, treatment discontinuation, as well as throughout the treatment period. Among the most frequently occurring adverse events in the liarozole group were dry skin (51% of patients), pruritus (25%), rash (16%), nail disorders (16%), and hair loss (15%). These adverse events were generally mild to moderate in severity and did not affect the overall quality of life score. There were no detectable effects of either treatment on vital signs such as blood pressure, heart rate, electrocardiogram, and body weight. Conclusions. Liarozole is superior to CPA in terms of PSA response, PSA progression, and survival, and is capable of maintaining patients' quality of life. The observed adverse events were mild to moderate in nature. These results show that liarozole is a possible treatment option after first-line endocrine therapy has failed.

AB - Objectives. To compare the efficacy of oral liarozole, the first retinoic acid metabolism-blocking agent (RAMBA) to be developed as differentiation therapy for human solid tumors, with that of cyproterone acetate (CPA), an antiandrogen for the treatment of metastatic prostate cancer. Liarozole promotes differentiation of cancer cells by increasing the intratumoral levels of retinoic acid. Methods. A total of 321 patients with metastatic prostate cancer in relapse after first-line endocrine therapy entered a Phase III international multicenter study (recruitment from February 1992 to August 1994) comparing liarozole (300 mg two times daily) with CPA (100 mg two times daily). Results. Accounting for differences in baseline prognostic factors, the adjusted hazard ratio for survival was 0.74 in favor of liarozole (P = 0.039), indicating a 26% lower risk of death than in patients treated with CPA. Median crude (unadjusted) survival time was the same in the liarozole group as in the CPA group (10.3 months). More patients showed a PSA response (at least 50% reduction in PSA from baseline) when treated with liarozole (20%) than with CPA (4%) (P <0.001). Prostate- specific antigen (PSA) responders had a median survival benefit of 10 months over nonresponders, irrespective of treatment (hazard ratio 0.43; P = 0.0018). PSA response was apparent within 3 months in approximately 90% of patients who responded. Pain improved more in the liarozole group than in the CPA group (P = 0.03). PSA responders had lower median pain scores than nonresponders (1.7 versus 2.5) and better quality of life (median Functional Living Index-Cancer score 108 versus 98) at end point, ie, treatment discontinuation, as well as throughout the treatment period. Among the most frequently occurring adverse events in the liarozole group were dry skin (51% of patients), pruritus (25%), rash (16%), nail disorders (16%), and hair loss (15%). These adverse events were generally mild to moderate in severity and did not affect the overall quality of life score. There were no detectable effects of either treatment on vital signs such as blood pressure, heart rate, electrocardiogram, and body weight. Conclusions. Liarozole is superior to CPA in terms of PSA response, PSA progression, and survival, and is capable of maintaining patients' quality of life. The observed adverse events were mild to moderate in nature. These results show that liarozole is a possible treatment option after first-line endocrine therapy has failed.

UR - http://www.scopus.com/inward/record.url?scp=0032126721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032126721&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(98)00129-0

DO - 10.1016/S0090-4295(98)00129-0

M3 - Article

C2 - 9671874

AN - SCOPUS:0032126721

VL - 52

SP - 72

EP - 81

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -